This study evaluated whether statin therapy changed a diagnostic validity of lipid and inflammatory markers in ischemic heart disease (IHD) patients. Levels of lipids, lipoproteins, apolipoproteins, inflammatory markers, and atherogenic indexes were determined in 49 apparently healthy men and women, 82 patients having stable angina pectoris (SAP), 80 patients with unstable angina (USAP), and 106 patients with acute ST-elevation myocardial infarction (STEMI) treated or not treated with statins. Diagnostic accuracy of markers was determined by ROC curve analysis. Significantly lower apoA-I in all statin-treated groups and significantly higher apoB in statin-treated STEMI group compared to non-statin-treated groups were observed. CRP showed the best ROC characteristics in the assessment of STEMI patients. Lp(a) is better in the evaluation of SAP and USAP patients, considering that Lp(a) showed the highest area under the curve (AUC). Regarding atherogenic indexes, the highest AUC in SAP group was obtained for TG/apoB and in USAP and STEMI patients for TG/HDL-c. Statins lowered total cholesterol, LDL-c, and TG but fail to normalize apoA-I in patients with IHD. 1. Introduction Beside endothelial dysfunction leading to inflammatory reaction, lipid metabolism disorders represent the second key event in the initiation and rapid development of atherogenesis [1]. Many individual lipid and inflammatory markers have been considered as the factors playing an important role in atherogenesis and prognosis of related diseases. The atherogenic dyslipidemic profile, especially mild to marked elevation of apo-B containing lipoproteins, such as very low-density lipoproteins (VLDL), VLDL-remnants, intermediate-density lipoproteins (IDL), and low-density lipoproteins (LDL) (specifically small, dense LDL), and low levels of high-density lipoproteins (HDL) [2–4], appears to promote enhanced arterial cholesterol deposition and accelerate the progression of atherosclerotic disease. Despite the use of new and effective pharmacological drugs to lower plasma lipid concentration, cardiovascular diseases continue to be the main cause of death in western countries [5, 6]. Fenofibrate lowers the plasma level of cholesterol and triglyceride, corrects the abnormality in LDL metabolism, but has no effect on HDL-cholesterol (HDL-c) [7]. On the other hand, statins have a therapeutic effect on lipid metabolism and inflammation. They lower total and LDL-cholesterol (LDL-c), elevate HDL-c, and lower inflammatory markers such as C-reactive protein (CRP) [8–11]. Since antilipidemic drugs induce
References
[1]
R. Ross, “Atherosclerosis—an inflammatory disease,” New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999.
[2]
M. R. Taskinen, “Diabetic dyslipidaemia: from basic research to clinical practice,” Diabetologia, vol. 46, no. 6, pp. 733–749, 2003.
[3]
K. J. Williams and I. Tabas, “Lipoprotein retention- and clues for atheroma regression,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 8, pp. 1536–1540, 2005.
[4]
N. A. Le and M. F. Walter, “The role of hypertriglyceridemia in atherosclerosis,” Current Atherosclerosis Reports, vol. 9, no. 2, pp. 110–115, 2007.
[5]
J. L. Breslow, “Cardiovascular disease burden increases, NIH funding decreases,” Nature Medicine, vol. 3, no. 6, pp. 600–601, 1997.
[6]
E. Braunwald, “Shattuck lecture cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities,” New England Journal of Medicine, vol. 337, no. 19, pp. 1360–1369, 1997.
[7]
C. J. Packard, “LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow,” Current Medical Research and Opinion, vol. 13, no. 7, pp. 379–390, 1996.
[8]
I. Jialal, D. Stein, D. Balis, S. M. Grundy, B. Adams-Huet, and S. Devaraj, “Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels,” Circulation, vol. 103, no. 15, pp. 1933–1935, 2001.
[9]
S. Kinlay, G. G. Schwartz, A. G. Olsson et al., “High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study,” Circulation, vol. 108, no. 13, pp. 1560–1566, 2003.
[10]
J. B. Muhlestein, J. L. Anderson, B. D. Horne et al., “Early effects of statins in patients with coronary artery disease and high C-reactive protein,” American Journal of Cardiology, vol. 94, no. 9, pp. 1107–1112, 2004.
[11]
M. A. Albert, E. Danielson, N. Rifai, and P. M. Ridker, “Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study,” Journal of the American Medical Association, vol. 286, no. 1, pp. 64–70, 2001.
[12]
Y. P. Jin, G. M. Qin, S. Z. Zhang, C. J. Li, and G. Xu, “Clinical evaluation of risk factors for coronary heart disease,” Zhonghua Yu Fang Yi Xue Za Zhi, vol. 37, no. 2, pp. 98–101, 2003.
[13]
G. Jürgens, W. C. Taddei-Peters, P. K？ltringer et al., “Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease,” Stroke, vol. 26, no. 10, pp. 1841–1848, 1995.
[14]
C. W. Hamm and E. Braunwald, “A classification of unstable angina revisited,” Circulation, vol. 102, no. 1, pp. 118–122, 2000.
[15]
F. Van de Werf, D. Ardissino, A. Betriu, et al., “Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation,” European Heart Journal, vol. 24, pp. 28–66, 2003.
[16]
V. B. Djordjevi？, I. Stojanovi？, V. ？osi？ et al., “Serum neopterin, nitric oxide, inducible nitric oxide synthase and tumor necrosis factor-α levels in patients with ischemic heart disease,” Clinical Chemistry and Laboratory Medicine, vol. 46, no. 8, pp. 1149–1155, 2008.
[17]
J. A. Navarro-Gonzálvez, C. García-Benayas, and J. Arenas, “Semiautomated measurement of nitrate in biological fluids,” Clinical Chemistry, vol. 44, no. 3, pp. 679–681, 1998.
[18]
G. A. Hobbs, I. V. Kaplan, and S. S. Levinson, “Mechanized lipoprotein(a) assay as a marker for coronary artery disease illustrates the usefulness of high lipoprotein(a) levels,” Clinica Chimica Acta, vol. 274, no. 1, pp. 1–13, 1998.
[19]
W. Herrmann, S. Quast, K. Wolter et al., “Determination of free apolipoprotein(a) in serum by immunoassay and its significance for risk assessment in patients with coronary artery disease,” Clinical Chemistry and Laboratory Medicine, vol. 37, no. 1, pp. 21–28, 1999.
[20]
A. B. Erba？ci, M. Tarak？io？lu, M. Aksoy et al., “Diagnostic value of CRP and Lp(a) in coronary heart disease,” Acta Cardiologica, vol. 57, no. 3, pp. 197–204, 2002.
[21]
L. E. Chambless, A. R. Folsom, A. R. Sharrett et al., “Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study,” Journal of Clinical Epidemiology, vol. 56, no. 9, pp. 880–890, 2003.
[22]
A. Bennet, E. Di Angelantonio, S. Erqou et al., “Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data,” Archives of Internal Medicine, vol. 168, no. 6, pp. 598–608, 2008.
[23]
R. S. Rosenson and C. C. Tangney, “Antiatherothrombotic properties of statins: implications for cardiovascular event reduction,” Journal of the American Medical Association, vol. 279, no. 20, pp. 1643–1650, 1998.
[24]
J. K. Plenge, T. L. Hernandez, K. M. Weil et al., “Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction,” Circulation, vol. 106, no. 12, pp. 1447–1452, 2002.
[25]
R. Altman, “Risk factors in coronary atherosclerosis athero-inflammations: the meeting point,” Thrombosis Journal, vol. 1, article 4, 2003.
[26]
S. Gonbert, S. Malinsky, A. C. Sposito et al., “Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk,” Atherosclerosis, vol. 164, no. 2, pp. 305–311, 2002.
[27]
P. M. Ridker, N. Rifai, N. R. Cook, G. Bradwin, and J. E. Buring, “Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women,” Journal of the American Medical Association, vol. 294, no. 3, pp. 326–333, 2005.
[28]
A. M. Gotto, E. Whitney, E. A. Stein et al., “Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS),” Circulation, vol. 101, no. 5, pp. 477–484, 2000.
[29]
S. Miremadi, A. Sniderman, and J. Frohlich, “Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders?” Clinical Chemistry, vol. 48, no. 3, pp. 484–488, 2002.
